Emiltatug ledadotin shows promising antitumor activity in various cancers, with manageable safety, highlighting its potential ...

An expert discusses how long-term follow-up data from the COMMANDS trial demonstrated sustained superiority of luspatercept ...

An expert discusses how the EPO-PRETAR trial results showed no significant difference in transfusion dependence between early ...

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, ...

During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed ...

The FDA prioritizes TAR-200 for treating high-risk bladder cancer, showcasing promising phase 2b study results and innovative ...

During a live event, Tony Philip, MD, and participants discussed molecular profiling and active surveillance for desmoid ...

Teclistamab shows promise for relapsed/refractory multiple myeloma patients with prior BCMA therapy, despite trends of reduced survival and response rates.

George Mulligan, PhD, previews the FDA's ODAC meeting discussing the application of belantamab mafodotin-based combinations for the treatment of multiple myeloma.